Market Overview

The Sell-Side Weighs In: Was The Exact Sciences Sell-Off Overdone?

Share:
The Sell-Side Weighs In: Was The Exact Sciences Sell-Off Overdone?

EXACT Sciences Corporation (NASDAQ: EXAS) stock tumbled nearly 10 percent Wednesday after the American Society of Clinical Oncology announced results from a new study on liquid biopsy tests for colorectal cancer that could pose a threat to EXACT’s Cologuard home screening test.

The new liquid biopsy test is up to 88 percent accurate, and co-author Ashish Nimgaonkar said more than 80 percent of patients who would prefer not to undergo a colonoscopy would also prefer a blood-based test to a stool-based test, according to the ASCO.

Clearly, the market sees the new test as bad news for EXACT, but here’s a sampling of what Wall Street analysts had to say  Wednesday.

Voices From The Street

Baird analyst Catherine Ramsey Schulte said Thursday’s weakness seems overdone. “On first glance, what stands out to us is the fact that out of 620 subjects, 111 (18 percent) had pre-cancer and another 327 (53 percent) had cancer, which likely skews the specificity much higher than if the study were done on the typical U.S. population,” Schulte said. 

Cowen analyst Doug Schenkel also used the word “overdone” to describe the market’s knee-jerk reaction. “The data looks interesting; however, this is a relatively small, single-site study that includes a disproportionate amount of diseased patients; there are also questions about study design,” he said. 

Canaccord Genuity analyst Mark Massero said investors should be aggressively buying EXACT on the dip. “In our opinion, this study is apples-and-oranges different than EXAS' Deep-C Study, which got Cologuard approved by the FDA and into guidelines,” Massero said. 

The new data also sparked a humorous Twitter debate between biotech expert Adam Feuerstein and QTR Research after QTR tweeted that EXACT shares “could honestly fall $10 on this news and still possibly be overvalued.”

Shortly after, QRT responded with a well-reasoned rebuttal.

Latest Ratings for EXAS

DateFirmActionFromTo
Aug 2019MaintainsBuy
May 2019MaintainsBuyBuy
May 2019MaintainsBuyBuy

View More Analyst Ratings for EXAS
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Price Target Reiteration Top Stories Analyst Ratings General Best of Benzinga

 

Related Articles (EXAS)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
BIOSSunTrust Robinson HumphreyMaintains4.3
TWNKSunTrust Robinson HumphreyMaintains16.0
EXPOSunTrust Robinson HumphreyMaintains81.0
DRISunTrust Robinson HumphreyMaintains139.0
AKRXSunTrust Robinson HumphreyMaintains4.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Morgan Stanley Upgrades Liberty Global, Says Lightning Has Struck

Credit Suisse: Encompass Health Is The Market Leader In Rehab, Home Health